Register

Pulmonology   

Questions discussed in this category

How would you manage a patient with morbid obesity who presents with new symptomatic pulmonary embolism a few days after he was started on DOAC for DVT?
What is your preferred anticoagulation in patients with BMI >50?
1 Answer available
Is an early chest tube and tPA/Dornase therapy for a loculated and complex pleural effusion that is not an empyema or hemothorax helpful in reducing the rate of developing trapped lung?
1 Answer available
What are your top takeaways from ATS 2023?
2 Answers available
What is your approach to the use of acetazolamide in patients with OSA?
1 Answer available
Do you start steroid therapy in a patient with pure ARDS without septic shock, or would you only consider steroids only in those with severe community acquired pneumonia?
To help interpret clinical applications of the CAPE COD (2023) and DEXA ARDS (2020) trials.
2 Answers available
How do you manage diarrhea in a patient with CTD-ILD on MMF who was recently started on full dose nintedanib?
5 Answers available
Do you perform spontaneous breathing trials on higher levels of PEEP with extubation to positive pressure ventilation in patients intubated for obesity hypoventilation syndrome?
1 Answer available
How are you using artificial intelligence in your clinic, if at all?
4 Answers available
How do you sequence pharmacologic treatments for primary insomnia?
4 Answers available
When do you begin antifibrotic therapy for a patient with newly diagnosed ILD that is not IPF?
Do you base the decision on FEV1, 6MWD or symptoms at initial evaluation, or progression over time?
6 Answers available
Do you routinely continue using TPA/Dornase for treatment of empyema, if there is accumulation of new sero-sanguinous output from the chest tube after the initial treatment?
Are there any quantitative indices (eg. volume, pleural fluid hematocrit) that would impact your decision to stop subsequent TPA/dornase treatments?
1 Answer available
What indicators do you use to determine whether a patient is having a favorable or unfavorable response to nintedanib?
When adding nintedanib what sort of treatment course do you counsel the patient on? Do you plan to continue it indefinitely as long as the patient tol...
3 Answers available
What is your approach to using nintedanib in patients on baseline immunosuppression?
Patients on baseline mycophenolate and azathioprine were excluded from the INBUILD trial however many patients with CTD-ILD will be on some form of im...
3 Answers available
Do you generally recommend starting nintedanib prior to immunosuppressive therapy in a patient with CTD-ILD?
Do you prefer to start with nintedanib and then add immunosuppressive agents, or give a trial of immunosuppressive medication first, then add nintedan...
4 Answers available
What is your approach to management of elderly patients with cardiopulmonary comorbidities and severe pulmonary hypertension?
1 Answer available
Do you screen for interstitial lung disease in patients with newly diagnosed polymyositis or dermatomyositis in the absence of respiratory symptoms?
3 Answers available
What is your threshold to start stress dose steroids in the management of patients with septic shock?
Do you do start therapy at a certain vasopressor requirement?
2 Answers available
How do you define an adequate EBUS when staging NSCLC?
Is there a minimum standard for which stations to sample? Does lymph node size affect your recommendations?
3 Answers available
What is your approach to initial work up for a young patient with bronchiectasis?
1 Answer available
Are you using NAC in lieu of hypertonic saline amidst the current shortage of hypertonic saline in patients with either CF or non-CF bronchiectasis?
1 Answer available
What is your approach to the monitoring and management of a never-smoker with respiratory symptoms and a nonspecific ventilatory pattern on pulmonary function testing?
1 Answer available
What dose and duration of steroid therapy do you use in steroid responsive ILD?
1 Answer available
What is your next step in management for a patient with immunotherapy induced pneumonitis that does not improve on high dose steroids for 48 hours?
How do you decide between starting infliximab, MMF, or IVIG? If a patient presents in respiratory failure (nearing or requiring intubation), woul...
1 Answer available
Do you employ the use of noctournal oximetry to assess for a need for supplemental O2 in addition to auto PAP in patients with OSA who have not had an in lab CPAP titration study?
2 Answers available
Do you continue methotrexate while starting TNFi therapy in patients with refractory pulmonary sarcoidosis?
3 Answers available
How do you choose between azithromycin and roflumilast in the management of a patient with severe COPD who remains symptomatic with frequent exacerbations despite maximal dose LABA/LAMA/ICS with demonstrated compliance and proper inhaler technique?
1 Answer available
Do you diagnose obstruction by the criteria of FEV1/FVC < 70% or < LLN?
3 Answers available
How do you approach treatment of septated parapneumonic pleural effusions that do not satisfy traditional criteria for complicated effusion after diagnostic thoracentesis?
Is there any role of tube thoracostomy as opposed to only antibiotics?
1 Answer available
Is there a role for biologics to help patients with ABPA who are steroid responsive and have removed their allergen insult, but continue to have an elevated serum IgE and incomplete resolution of symptoms return to their baseline functional status?
2 Answers available
How do you define severe hypoxic burden on home sleep testing?
1 Answer available
What is the optimal frequency and duration of post-operative radiological surveillance following resection of a solitary fibrous tumor?
1 Answer available
What is your perspective on the role of respiratory therapists in managing a patient who is dyssynchronous on their current mode of mechanical ventilation?
Do your respiratory therapists independently adjust ventilator settings without direct physician involvement?
2 Answers available
Do you offer immunosuppression to patients with CTD-ILD with concomitant well controlled HIV?
2 Answers available
For NSCLC patients with limited diagnostic tissue that is insufficient for genetic testing, do you offer repeat biopsy (of accessible site), blood based testing, or both to evaluate for actionable driver mutations?
3 Answers available
What is the role for "liquid biopsy" for patients with newly diagnosed metastatic NSCLC?
6 Answers available
Are you using the microbial cell-free DNA “Karius” test to aid in the diagnosis of an atypical pulmonary infection such as PJP or NTM?
2 Answers available
Do you use steroids in patients with respiratory failure who are infected with both influenza and COVID-19?
How do you approach which risk to accept given that steroids have evidence for use in COVID-19 while is suggestion for harm in using steroids in influ...
1 Answer available
What is your approach to volume resuscitation in patients with obvious septic shock but also with a component of suspected cardiogenic shock?
4 Answers available
Do you use prednisone in the management of patients with persistent respiratory symptoms following acute COVID-19 infection?
4 Answers available
How do you manage recurrent inflammatory pleural effusions in lupus pleuritis?
1 Answer available
What is your approach to counseling a patient with exertional hypoxia, but normal resting oxygen saturation, who is hesitant to use supplemental oxygen therapy?
1 Answer available
What is your approach to steroid sparing therapy in patients with suspected CTD-ILD?
1 Answer available
What strategies do you employ to prevent post-intubation hypotension in a profoundly hypoxic patient given a paralytic for intubation?
1 Answer available
How do you complete brain death testing in patients who cannot tolerate apnea testing and are unable to transport for ancillary testing?
For instance, if the patient doesn’t tolerate apnea testing, is too unstable to go for ancillary testing outside the ICU, and TCDs/EEG are unava...
5 Answers available
What steroid regimen do you employ prior to extubating a patient who does not have a suitable cuff leak?
2 Answers available
What is your approach to therapy for pulmonary sarcoidosis resistant to methotrexate?
1 Answer available
What steroid regimen do you use in patients with both septic shock and ARDS?
Do you use hydrocortisone 200 mg/day as studied in ADRENAL/APROCCHSS or dexamethasone 20 mg/day as studied in DEXA-ARDS?
2 Answers available
How would you treat a patient with combined pre- and post-capillary pulmonary hypertension after successfully optimizing post-capillary pressures through a valvular intervention?
2 Answers available
Do you consider the duration of lung/lobar atelectasis in your decision making while offering airway stents for malignant central airway obstruction?
Are patients with long standing malignant central airway obstruction poor candidates for central airway stents? What is considered to be an acceptable...
1 Answer available
Is there any role for palliative radiation in patients who are intubated due to malignant airway obstruction?
Given the substantial risks associated with transporting an intubated and ventilated patient to Radiation Oncology, is there any evidence to support t...
5 Answers available
Do you routinely isolate and test for TB in a patient incidentally found to have a miliary pattern of nodules on chest CT?
2 Answers available
Do you routinely use vasopressin in the management of RV failure leading to shock state in the absence of an obvious treatable cause such as infarction or PE?
2 Answers available
What is your approach to pulmonary vasodilator therapy in patients with COPD and Severe Group 3 Pulmonary Hypertension?
1 Answer available
Do you use acetazolamide to aid diuresis in patients with acute on chronic respiratory acidosis with significantly elevated serum bicarbonate levels?
2 Answers available
Do you continue CFTR modulator therapy in patients with extra-pulmonary manifestations of CF after lung transplant?
1 Answer available
What is your threshold to start triple therapy in mild to moderate asthma/COPD overlap with minimal functional limitation?
1 Answer available
What are your preferred ventilatory settings/mode(s) for patients with acute hypoxic respiratory failure presenting with severe biventricular dysfunction in cardiogenic shock?
1 Answer available
Does your approach to the management of a patient with an acute exacerbation of CPFE where the ILD is attributed to IPF differ from the management of a patient with an exacerbation of IPF alone?
1 Answer available
Would you restart prophylactic anticoagulation in a patient with a history of unprovoked PE who received short term anticoagulation with a prior physician?
E.g. low dose DOAC
1 Answer available
What is your preferred management for diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH)?
Does your management change if symptomatic or asymptomatic?
1 Answer available
How would you manage immune check point inhibitor induced capillary leak syndrome refractory to IVIG monotherapy?
1 Answer available
Do you routinely use donor derived cell free DNA levels to guide surveillance bronchoscopies in lung transplant recipients?
2 Answers available
Would you give checkpoint inhibitor therapy to a cancer patient with known dermatomyositis given the association of checkpoint inhibitor associated myocarditis, myasthenia gravis, and myositis?
6 Answers available
Is there a role of everolimus or capecitabine and temozolomide in diffuse idiopathic pulmonary neuroendocrine cell hyperplasia in patients already on octreotide?
1 Answer available
What is your approach to therapy in patients with progressive Scedosporium pulmonary infection who are not candidates for surgical debridement?
1 Answer available
How do you monitor for pulmonary toxicity for patients on trastuzumab deruxtecan?
Would you obtain baseline PFT on all patients or only selected high risk patients? Would you repeat PFTs regularly or only if clinically symptomatic?&...
5 Answers available
Does the presence of interstitial lung disease affect your decision to offer SBRT for early stage NSCLC?
Specifically in O2-dependent patients? Have any dose/fractionation regimens been shown to reduce the risk of pneumonitis in this population?
3 Answers available
Do you routinely use milrinone to augment RV function in patients with massive pulmonary emboli on vasoactive support?
1 Answer available
How do you approach management of limited stage SCLC in a patient with idiopathic pulmonary fibrosis?
3 Answers available
What is your approach to the management of a patient with PAH who is resistant to contraception and planning a pregnancy?
1 Answer available
Are there known biomarkers predictive of IRAEs?
3 Answers available
Do you routinely use sweat tests if you are going to titrate a CF patient onto a lower dose of ETI for any reason (allergy, mental health, etc) to assess the severity of their response to the lower dose?
1 Answer available
Are there any concerns utilizing apremilast for psoriatic arthritis in patients who are also taking roflumilast for COPD?
1 Answer available
Do you prescribe antifibrotics to patients with combined pulmonary fibrosis and emphysema (CPFE)?
1 Answer available
When can abdominal surgery be safely performed for presumptive ovarian cancer in a patient with recent pulmonary emboli?
(Normal oxygenation and echo)
1 Answer available
Is there any PFT criteria that you use in guiding decision making to offer transbronchial lung cryobiopsy to patients with interstitial lung disease?
1 Answer available
What are your top takeaways from CHEST 2022?
2 Answers available
Do you favor the use of maximal inspiratory/expiratory pressure measurement or supine spirometry in the evaluation of a patient with suspected respiratory muscle weakness?
1 Answer available
What is your preferred first line treatment for chronic fatigue in patients with long Covid?
2 Answers available
What is your approach to counseling and management of patients with severe symptomatic OSA whose PAP devices have been recalled?
1 Answer available
Do you treat Candida spp isolated from a bronchoalveolar lavage?
1 Answer available
How do you manage steroid-refractory immune checkpoint inhibitor induced pneumonitis?
4 Answers available
Is there a role for biologic therapies in asthma-COPD overlap syndrome with evidence of type 2 inflammation?
2 Answers available
Do you start PAP in patients who have an overall AHI of less than 5 but demonstrate significant apneas/hypopneas in REM sleep?
1 Answer available
What is your approach to the work up and management of interstitial lung abnormalities?
1 Answer available
How do you approach performing EBUS TBNA in patients with latex allergy?
Apart from removing the latex balloon, do you employ any additional technical accommodations?
1 Answer available
Do you routinely continue airway clearance therapies in the setting of mild to moderate hemoptysis in a patient with CF?
2 Answers available
Would you consider prophylactic antifungal treatment prior to immunosuppressive therapies in a patient with previously treated pulmonary coccidiomycosis and residual parenchymal changes?
1 Answer available
Do you often see clinical improvement that is significant enough to de-list patients with CF for transplant after the initiation of CFTR modulator therapy?
2 Answers available
Do you ever stop tobramycin prophylaxis in a patient with chronic bronchiectasis previously colonized with pseudomonas?
2 Answers available
Do you perform a clamp trial before removing a chest tube for pneumothorax?
2 Answers available
Do you do recommend further mediastinal staging for patients with SCLC or inoperable NSCLC with N1 disease on PET?
If a patient clearly has N1 disease with high SUV on PET, do you routinely recommend EBUS or mediastinoscopy to evaluate for N2 disease?
1 Answer available
What is your preferred steroid sparing therapy in a patient experiencing a severe checkpoint inhibitor toxicity and not responding to high dose IV steroids?
2 Answers available
What patient characteristics would lead you to opt for triple therapy versus double therapy in newly diagnosed PAH?
1 Answer available
Do you give intrapleural lytics for complicated effusion/empyema in patients on systemic anticoagulation?
1 Answer available
What patient related factors and hemodynamic parameters would lead you to avoid transbronchial biopsies in patients with pulmonary hypertension?
1 Answer available
What steroid regimen do you employ in the treatment of patients with post COVID-19 pulmonary fibrosis?
2 Answers available
Do you ever employ the use of prolonged periods of pressure support ventilation as means of "weaning" in the management of patients with acute respiratory failure?
1 Answer available
How would you manage subclinical ILD associated with MDA-5 Dermatomyositis?
Any indications for triple therapy in the patients with subclinical ILD associated with MDA-5 dermatomyositis?
1 Answer available
Would you consider PLEX for patients with DAH from SLE-associated capillaritis?
1 Answer available
How frequently do you monitor LFTs and CBC after initiating endothelin receptor antagonists?
Is there a difference in monitoring frequency for legacy drugs like bosentan vs newer agents (macitentan, ambrisentan)?
3 Answers available
Do you find that complete interlobar fissures on HRCT correlate well with decreased collateral ventilation on endoscopic balloon occlusion in the evaluation and placement of endobronchial valves for bronchoscopic lung volume reduction?
2 Answers available
Do you favor the use of Fick or thermodiluation to measure cardiac output in patients with interstitial lung disease with suspected pulmonary hypertension?
Occasionally, supplemental oxygen may alter Fick measurements giving falsely high CO and falsely low PVR, therefore is Thermodilution method preferred...
2 Answers available
Do you ever initiate pirfenidone in patients with CTD-ILD?
1 Answer available
Which images do you routinely request when ordering a HRCT chest?
1 Answer available
In a patient with history of pneumonectomy would you consider SBRT for treatment of a new tumor in the remaining lung?
1 Answer available
How do you prescribe a steroid taper for radiation and checkpoint inhibitor related pneumonitis?
I've seen a handful of fatal radiation pneumonitis associated with rapid steroid tapers by the non-treating physicians. How do you recommend prescribi...
1 Answer available
Do you prefer using end-expiratory or mean pulmonary artery wedge pressure obtained during diagnostic right heart catheterization for the classification of precapillary vs postcapillary PH?
1 Answer available
When do you consider Balloon Pulmonary Angioplasty in patients with inoperable CTEPH?
1 Answer available
Do you consider extensive clot burden as a factor in determining whether patients with submassive PE may be appropriate for thrombolytic therapy?
3 Answers available
Do you consider endobronchial valve lung volume reduction in patients with homogenous emphysema?
1 Answer available
What is the risk of ILD recurrence in MDA5/Ro52 positive dermatomyositis following a lung transplantation?
1 Answer available
Do you consider the use of bevacizumab in patients with HHT who have high output cardiac failure related to liver AVMs who also have cerebral AVMs?
1 Answer available
What workup do you do for patients who have PL-7 elevation when screening for myopathy?
2 Answers available
Do you routinely use inhaled pulmonary vasodilators in the management of patients with ARDS with refractory hypoxemia?
1 Answer available
Do you routinely perform genetic testing in patients presenting with pulmonary fibrosis who endorse a family history of fibrotic lung disease?
1 Answer available
Do you recommend the use of endobronchial valves in the management of patients with spontaneous pneumothorax with persistent air leak?
1 Answer available
What are your top takeaways in Thoracic Cancers from ASCO 2022?
What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice?
6 Answers available
How long do you continue surveillance with imaging and sputum cultures in a patient with NTM with no indications for treatment?
1 Answer available
Would you consider the use of dual antifibrotic therapy (nintedanib and pirfenidone together) for progressive fibrosing ILD?
3 Answers available
Do you recommend the use of indwelling pleural catheters in the management of patients with hepatic hydrothorax requiring frequent drainage?
1 Answer available
What criteria do you use to consider pleurodesis vs indwelling tunneled catheters in patients with malignant pleural effusion?
1 Answer available
How do you counsel patients regarding prognosis following a diagnosis of IPF?
1 Answer available
How do you approach a thoracic lymph node that is highly suspicious on CT and PET but negative on EBUS in patients with NSCLC?
3 Answers available
Is there a role for immunosuppression in addition to standard PAH therapy in the management of pulmonary hypertension associated with primary Sjogrens syndrome?
Assuming other non CTD related causes for PAH have been excluded
1 Answer available
Do you adjust immunosuppression in lung transplant recipients diagnosed with COVID-19?
2 Answers available
Is there a role for the use of inhaled corticosteroids in patients with pulmonary sarcoidosis who have stage II or III disease with abnormal lung function but only mild respiratory symptoms?
1 Answer available
How do you clinically distinguish between group I and group III PH in patients with CTD-ILD?
1 Answer available
Do you utilize soluble IL-2 receptor or ACE levels as serum biomarkers to monitor disease activity in pulmonary sarcoidosis?
1 Answer available
Based on findings of the INCREASE trial, are you routinely prescribing inhaled treprostinil to patients with group 3 pulmonary hypertension secondary to interstitial lung disease?
1 Answer available
How do you manage a stenotic airway following SBRT or hypofractionated radiation to a central lung tumor?
Are there situations in which you would recommend dilation of stenotic airways after radiation? Is there a concern for increased complications of dila...
1 Answer available
How do you treat patients with sarcoid who have persistent symptoms after an initial 6 week course of corticosteroids?
3 Answers available
Do you consider the use of antifibrotics at presentation in patients with a radiographic UIP pattern of pulmonary fibrosis in the presence of positive serologies without any symptoms of CTD (ie, fulfilling a possible diagnosis of IPAF) who have not yet demonstrated evidence of a progressive phenotype?
1 Answer available
Do you de-escalate airway clearance therapies in patients with CF who experience an improvement in mucus production and clearance after CFTR modulator therapy is started?
1 Answer available
Do you employ the use of extracorporeal photopheresis in the management of patients with progressive BOS following lung transplantation?
Clinical trial NCT02181257 to explore this currently in process
1 Answer available
Do you employ the use of external chest compression with sandbags in the management of patients with severe ARDS who are not candidates for proning?
1 Answer available
When would you consider biopsy for an incidentally noted, PET negative, solid, solitary pulmonary nodule that is >8mm in size?
1 Answer available
Is there a role for antifibrotic therapy in post COVID-19 pulmonary fibrosis?
1 Answer available
Do you use intrapleural tPA/dornase in loculated effusions that are not due to infection?
1 Answer available
Do you consider EBUS TBNA in the diagnostic evaluation of patients with mediastinal lymphadenopathy with concern for lymphoma?
1 Answer available
What are best practices for engaging with multidisciplinary colleagues to ensure patients with earlier stage NSCLC are being appropriately considered for novel adjuvant therapies?
How are your teams effectively evaluating and counseling patients to ensure they are prepared for potential extended adjuvant treatment approaches? Is...
4 Answers available
What is your approach to treatment for a patient with progressive ILD (UIP pattern) with high titer RF but no articular symptoms?
1 Answer available
Would you advise a patient with quiescent vasculitis who flared with the first Covid mRNA vaccine to obtain an additional dose?
Would you suggest switching to a viral vector vaccine, such as J&J?
2 Answers available
Would you offer adjuvant chemotherapy, osimertinib, or both to a patient with Stage IB EGFR mutated lung adenocarcinoma found in the lung explant pathology after bilateral lung transplant?
Would you consider the immune suppressed status of the patient as a high risk factor to offer adjuvant therapy?
1 Answer available
How do you treat multisystem sarcoidosis refractory to methotrexate, humira, and remicade?
2 Answers available
What strategies can be employed to manage interstitial lung disease seen with trastuzumab deruxtecan?
Can patients be re-challenged after developing ILD? Is the toxicity seen with T-Dxd a potential barrier to use?  Do you feel the dosing used in...
2 Answers available
How would you approach treatment for fulminant RA-associated ILD?
Would you discontinue Methotrexate and TNF inhibitors even if previously no side effects from these medications, and would you consider Cyclophosphami...
1 Answer available
Have you seen rheumatoid nodules or RA-ILD in patients with seronegative RA?
While classically described as seen in seropositive patients, have they been reported in seronegative RA?
2 Answers available
What are your recommendations regarding methotrexate usage in patients with persistent chest CT changes post COVID pneumonia?
Would you have a different opinion based on whether it is a new therapy or an existing and previously well-tolerated therapy for the patient?
2 Answers available
How do you evaluate a suspicious, but negative pleural effusion when working up NSCLC and SCLC?
Are two negative pleurocentesis' adequate to conclude that the patient does not have metastatic disease? Do you routinely recommend VATS and pleural b...
1 Answer available
What is your approach for disease activity monitoring in patients with sarcoidosis?
1 Answer available
Do you routinely recommend a sleep study in patients with clinical history of REM-sleep behavior disorder?
Does this add any value?
1 Answer available
What criteria do you use on echocardiogram and PFT to determine who needs further evaluation for CTD-associated pulmonary hypertension?
1 Answer available
What indicators do you use to identify patients with CTD-ILD who do not have potential to improve from continued immunosuppressive therapy?
Do you use imaging (fibrosis vs. pneumonitis), PFTs, duration of prior immunosuppressive therapy?
1 Answer available
What is your preferred regimen for remission induction and maintenance in EGPA with cardiac involvement?
1 Answer available
How do you approach patients with ANCA vasculitis who had partial response, but continue to have disease activity on q 6 month maintenance rituximab and remain on steroids?
Would you change rituximab maintenance dose or schedule?
1 Answer available
How do you choose between oral and IV cyclophosphamide for the treatment of ANCA-associated vasculitis?
1 Answer available
What is your approach for a symptomatic inpatient with locally advanced NSCLC who cannot have a PET?
Would you consider treating the full mediastinum or any mildly enlarged nodes, even contralateral? Do you have a strategy that transitions from a pall...
2 Answers available
What immunosuppressive agents aside from steroids would you use to treat bronchiolitis obliterans in a patient with long-standing seropositive RA?
1 Answer available
How do you approach the management of SSc-ILD in a patient on immune checkpoint therapy?
1 Answer available
Would you use inhaled steroids with or without oral steroids for the treatment of radiation pneumonitis?
Would inhaled steroids help reduce the PO dose and/or significantly accelerate tapering?  If s, for what pneumonitis grade? What specific steroid...
1 Answer available
How do you treat an AAV patient with recurrent bronchial stenosis that has not responded to rituximab induction therapy and dilatations?
1 Answer available
Are there any concerns about using nintedanib in a patient with progressive fibrosing ILD on background mycophenolate?
1 Answer available
What is your initial treatment of choice in patients with RA and associated interstitial lung disease?
1 Answer available
Is positive pleural fluid cytology from pleural mesothelioma considered M+?
Should patient be considered for definitive therapy or chemo alone if pleural cytology positive but no T4, N2, or sarcomatoid features?
1 Answer available
How do you treat CTD-associated organizing pneumonia?
How is your approach to treatment different than other ILD patterns such as NSIP? Does treatment response vary based on underlying CTD?
2 Answers available
How will you use tocilizumab in the treatment algorithm for SSc-ILD, given its recent FDA approval?
1 Answer available
How do you treat RA in patients with pulmonary mycobacterium avium complex (MAC) infections?
1 Answer available
How do you manage end-organ toxicity such as hepatotoxicity or pulmonary toxicity in a patient receiving RET-inhibitors for NSCLC?
3 Answers available
What is your approach to treatment for MDA5 dermatomyositis patients with rapidly progressive ILD?
Cyclophosphamide/tacrolimus and Rituximab have been used in conjunction with steroids in case series.
1 Answer available
Is there a role for anti-IL6 therapy in SSc-associated ILD?
1 Answer available
Are there AAV patients for whom you would consider combination therapy with cyclophosphamide and rituximab?
1 Answer available
Can liquid biopsy be substituted for tissue biopsy in a lung mass that is radiologically suspicious for primary lung cancer when CT-guided biopsy cannot be done?
For example, a patient with a large (>3cm), spiculated, FDG-avid lung lesion, who has poor lung function and is refusing a CT-guided biopsy?
2 Answers available
What is considered an adequate treatment period to assess response of AAV induction therapy with rituximab or cyclophosphamide? 
1 Answer available
Which EGPA patients are most likely to benefit from treatment with anti-IL-5 agents such as mepolizumab?
1 Answer available
Should MTX be avoided in RA patients with asymptomatic lung nodules?
If so, what would be an ideal DMARD in this setting?
1 Answer available
What is the optimal management of patients with stage II lung cancer without nodal metastasis, but unresectable due to poor pulmonary reserve?
For T2bN0 or T3N0 disease, you consider radiation alone, sequential radiation followed by chemotherapy, or concurrent chemoradiation?
2 Answers available
Do you consider cystic fibrosis a contraindication to lung SBRT for primary NSCLC or oligometastases?
1 Answer available
How would you manage a patient with newly diagnosed locally advanced NSCLC and concurrent, active tuberculosis on anti-TB therapy?
After initiation of anti-TB treatment and 3 negative AFB smears, would you initiate concurrent chemoRT? Would you give sequential RT then chemo to giv...
1 Answer available
Which ANCA vasculitis patients are better candidates for cyclophosphamide rather than rituximab?
2 Answers available
Is there a role for monitoring serum ANCAs to assess ANCA associated vasculitis disease activity?
This question is part of a collaboration with RheumMadness and is in reference to: Pathogenic ANCARAVE Trial
1 Answer available
How does your treatment algorithm differ for drug-induced ANCA vasculitis compared to non drug-induced ANCA vasculitis in cases with severe/organ-threatening manifestations?
1 Answer available
Are there certain subsets of ANCA vasculitis patients for whom you would consider life long maintenance therapy?
2 Answers available
When a patient presents with 2 lung lesions, do you routinely recommend a biopsy of both lung lesions?
Would your practice change if the patient had N2 disease?
1 Answer available
Should methotrexate be categorically avoided in RA patients with COPD or RA-ILD?
1 Answer available
What clinical factors do you use to determine timing of on-demand dosing of rituximab in ANCA vasculitis maintenance therapy?
1 Answer available
Do you recommend on-demand versus fixed-schedule dosing for rituximab maintenance in ANCA vasculitis?
 If you use both, how do you decide which to use for a particular patient?
2 Answers available
What is the role of nintedanib in the treatment of SSc-ILD?
The SENSCIS trial was published in 2019 on efficacy of this agent. However, it's not clear where this should be in the treatment algorithm: Monot...
2 Answers available
When do you use tacrolimus in patients with myositis-related interstitial lung disease?
1 Answer available
How do you manage early and symptomatic fibrosis in lung cancer patients after RT?
I’ve noticed some patients develop worsening SOB and DOE months after RT and rather than interstitial diffuse pattern you would see with pneumon...
2 Answers available
Is there a subset of ANCA vasculitis patients for which you would try plasma exchange?
1 Answer available
What agent do you try next in patients with myositis-related interstitial lung disease who are refractory to mycophenolate mofetil and azathioprine?
1 Answer available
When do you stop immunosuppressants in patients with GPA?
1 Answer available
What is your next step in patients with polymyositis without interstitial lung disease who are refractory to methotrexate?
1 Answer available
Is there an increased risk of pneumonitis in COVID-19+ patients receiving lung irradiation?
Any differences in the risks between SBRT vs. conventionally fractionation? Concurrent immunotherapy? 
1 Answer available
How do you treat extensive stage small cell lung cancer in the very elderly (more than 80 yrs)?
1 Answer available
Do you use an age limit cutoff for SBRT in lung cancer?
Is there a certain age beyond which it is not safe to do SBRT?
1 Answer available
How has COVID-19 altered your recommendations for invasive mediastinal staging for NSCLC?
Should staging and treatment decisions be made based on imaging alone?
2 Answers available
How would you treat a patient with extensive-stage small cell carcinoma and severe end-stage COPD on home oxygen?
Would you treat with chemotherapy (carboplatin/etoposide) vs anti-pd-1 monotherapy vs combination chemoimmunotherapy vs supportive care?
2 Answers available
In a patient with ILD and metastatic NSCLC with positive PD-L1, would you give chemo/pembrolizumab, chemotherapy alone, or pembrolizumab alone?
Does the degree of PD-L1 expression weigh into your decision? 
1 Answer available
How do you approach elderly patients with stage III NSCLC who have a reasonable performance status?
Do you recommend or make any modifications in the PACIFIC regimen for patients > 75 years of age?
1 Answer available
How do you identify immunotherapy-related pneumonitis vs. radiation pneumonitis in a patient status post chemoradiation receiving consolidation immunotherapy?
Is IO related pneumonitis in the radiation field or more diffuse?
1 Answer available
What is your approach for a primary tracheal squamous cell carcinoma?
If clinically node negative, would you add elective nodal radiation?Does it depend on location (upper vs. lower trachea)?
1 Answer available
Should patients with idiopathic pulmonary fibrosis be placed on nintedanib or pirfenidone before starting radiotherapy for lung cancer?
1 Answer available
How important is a severely diminished diffusion capacity in determining whether to offer a lung cancer patient radiotherapy?
Does it factor into your decision making in the setting of restricted spirometry and normal lung volumes? Does this differ for SBRT v. chemoRT?
1 Answer available
How would you manage palliation in a patient with postobstructive pneumonia caused by a mediastinal mass?
Would you treat if there is active infection?  How much improvement would you expect?
1 Answer available
How are you using liquid biopsy in the routine management of your patients with metastatic NSCLC?
Are you using ctDNA blood tests for targetable mutations at the time of diagnosis, at the time of disease progression, or not at all?
2 Answers available
How do you approach the workup of subcentimeter contralateral nodules in cases of locally advanced NSCLC?
When there is biopsy proven mediastinal disease, do you offer definitive chemoradiation and monitor, or do you try to prove the presence/absence ...
1 Answer available
What factors do you consider to help guide treatment for patients with high grade large cell neuroendocrine cancers of the lung?
Do you incoprate Ki67% or mitotic rate into your treatment decision, and is there any use for somatostatin based imaging such as octreoscan or gallium...
1 Answer available
How do you manage an adult primary rhabdomyosarcoma of the lung/mediastinum?
Is there any role for consolidative RT/CRT to the lung and mediastinum after initial chemo? What dose and fractionation would be most appropriate for ...
1 Answer available
Do you consider idiopathic pulmonary fibrosis a contraindication to lung SBRT?
There are varying reports in the literature which seem to suggest increased rates of Gr 4-5 pneumonitis in IPF patients.  How do you manage these...
2 Answers available
Do you use anti-PD-1/anti-PD-L1 therapies in lung cancer patients with a prior history of radiation pneumonitis?
What about patients who are still on steroids for radiation pneumonitis? 
1 Answer available
When is it considered inappropriate to omit pathological mediastinal lymph node staging for non-small cell lung cancer?
The NCCN guidelines call for pathological mediastinal lymph node staging for all NSCLC except in solid tumors <1cm and non-solid lesions < ...
3 Answers available
When do you start steroids for radiation pneumonitis?
Following lung RT, I have rarely seen patients present with pneumonia-like symptoms of radiation pneumonitis. I'm more likely to see a patient with wo...
3 Answers available
How do you approach lung tumors with vessel encasement, especially in someone with active hemoptysis?
Is there any concern about hemorrhage from treatment effect on tumor? Would SABR worsen the chance of fatal hemorrhage/hemoptysis and if so, would you...
1 Answer available
What are your criteria for treating a patient with lung SBRT in the absence of a biopsy?
Roughly what percentage of patients are treated without a biopsy?
1 Answer available
If a PET/CT scan is positive for mediastinal lymph node involvement, is a mediastinoscopy or EBUS still required for NSCLC staging?
In practice, do you send patients with N2/3 disease for mediastinal staging if not offered upfront?
1 Answer available


Papers discussed in this category

Radiother Oncol, 2011 Nov
Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with a contemporaneous cohort with pathologically proven disease.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-10-20
Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer.
J Thorac Cardiovasc Surg, 2011 Mar
Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial.
Semin Radiat Oncol, 2015 Oct
Predicting Radiotherapy Responses and Treatment Outcomes Through Analysis of Circulating Tumor DNA.
J. Clin. Oncol., 2008-07-20
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Chest, 2007 Sep
Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).
JCO Precision Oncology, 2017 Sep 29
Circulating Tumor DNA in Non–Small-Cell Lung Cancer: A Primer for the Clinician
Sci Rep, 2014 Sep 09
Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis.
Medicine (Baltimore),
Blood as a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-10-01
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.
Lung cancer (Amsterdam, Netherlands), 1994-03
Toxicity of thoracic radiotherapy on pulmonary function in lung cancer.
Clin Lung Cancer, 2017 Jul 10
Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival in Patients Treated With Lung Stereotactic Body Radiation Therapy (SBRT).
J Thorac Oncol,
Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after stereotactic body radiation therapy for lung cancer.
Clinical lung cancer, 2018-07
Fatal Radiation Pneumonitis in Patients With Subclinical Interstitial Lung Disease.
Int. J. Radiat. Oncol. Biol. Phys., 2017 Mar 15
Treatment-Related Toxicity in Patients With Early-Stage Non-Small Cell Lung Cancer and Coexisting Interstitial Lung Disease: A Systematic Review.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2016-06
Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR).
Int. J. Radiat. Oncol. Biol. Phys., 2010-06-01
Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study.
Thorac Cancer, 2017 Apr 24
Relationship between endobronchial ultrasound-guided (EBUS)-transbronchial needle aspiration utility and computed tomography staging, node size at EBUS, and positron emission tomography scan node standard uptake values: A retrospective analysis.
International journal of radiation oncology, biology, physics, 2013-03-01
Poor baseline pulmonary function may not increase the risk of radiation-induced lung toxicity.
Respir. Res., 2018 Apr 24
Abnormal pulmonary function tests predict the development of radiation-induced pneumonitis in advanced non-small cell lung Cancer.
Radiographics : a review publication of the Radiological Society of North America, Inc, 2004
Effects of radiation therapy on the lung: radiologic appearances and differential diagnosis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-03
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.
The New England journal of medicine, 2015-07-16
Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy.
N Engl J Med, 2017 Nov 16
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
The New England journal of medicine, 2018-12-06
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-01-10
Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014-04
Management of mediastinal relapse after treatment with stereotactic body radiotherapy or accelerated hypofractionated radiotherapy for stage I/II non-small-cell lung cancer.
Clinical lung cancer, 2017-07
Stereotactic Body Radiotherapy for Large (> 5 cm) Non-Small-Cell Lung Cancer.
Int. J. Radiat. Oncol. Biol. Phys., 2020 Feb 07
Definitive Management of Presumed Synchronous Early Stage Non-Small Cell Lung Cancers: Outcomes and Utility of Stereotactic Ablative Radiation Therapy.
Cureus, 2019 Jun 22
Moderately Hypofractionated Radiotherapy Alone for Stage I-IIB Non-small Cell Lung Cancer.
Lung Cancer, 2009 Jan 24
Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus.
Radiat Oncol, 2016 Dec 03
SBRT for centrally localized NSCLC - What is too central?
Adv Radiat Oncol, 2020 May 05
Need for Caution in the Diagnosis of Radiation Pneumonitis in the COVID-19 Pandemic.
Cancer Discov, 2020 May 01
Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.
Lancet, 2020 May 28
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Int. J. Radiat. Oncol. Biol. Phys., 2020 Apr 14
Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement.
The New England journal of medicine, 2010-07-15
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
Medicine (Baltimore),
The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort.
The New England journal of medicine, 2010-07-15
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
N. Engl. J. Med., 2019 May 20
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
The Lancet. Respiratory medicine, 2016-09
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
The New England journal of medicine, 2006-06-22
Cyclophosphamide versus placebo in scleroderma lung disease.
J Thorac Oncol, 2020 Feb 24
A Primer on Interstitial Lung Disease and Thoracic Radiation.
Cancer Treat Rev, 2022 Mar 12
Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management.
Archives of internal medicine, 2008-09-22
Methotrexate is not associated with progression of interstitial lung disease in rheumatoid arthritis.
Arthritis and rheumatism, 2010-06
Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study.
Ann. Rheum. Dis., 2018 Apr 25
Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).
Ann. Rheum. Dis., 2017 May 25
Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis.
Ann. Rheum. Dis., 2018 May 03
Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
Chest, 2007-07
Natural history of stage I non-small cell lung cancer: implications for early detection.
Radiat Oncol, 2016 Apr 18
The clinical results of proton beam therapy in patients with idiopathic pulmonary fibrosis: a single center experience.
Journal of the National Cancer Institute, 2011-10-05
Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.
BMC Cancer, 2018 Oct 12
Efficacy and safety of concurrent anti-Cancer and anti-tuberculosis chemotherapy in Cancer patients with active Mycobacterium tuberculosis: a retrospective study.
The New England journal of medicine, 2017-05-18
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.
Kidney international reports, 2018-03
Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis.
N Engl J Med, 2020 Feb 13
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.
Rheumatology (Oxford),
A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis.
Lancet Respir Med, 2020 Aug 28
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.
N Engl J Med,
Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease.
Nature reviews. Rheumatology, 2018-05
Treatment in myositis.
Trials, 2017 Jun 15
Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.
N Engl J Med, 2019 Sep 29
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Arthritis Rheumatol, 2021 Feb 03
Tocilizumab Prevents Progression of Early Systemic Sclerosis Associated Interstitial Lung Disease.
N Engl J Med, 2012 May 20
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Journal of thoracic disease, 2013-12
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.
Thorac Surg Clin, 2020 Sep 12
The Staging of Malignant Pleural Mesothelioma.
Sleep Med Rev, 2021 Jun 10
REM sleep behavior disorder: Mimics and variants.
J Heart Lung Transplant, 2021 Nov
Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.
Interact Cardiovasc Thorac Surg, 2015 Jan 07
Recurrent polymyositis-associated lung disease after lung transplantation.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010-02
Split-course palliative radiotherapy for advanced non-small cell lung cancer.
International journal of radiation oncology, biology, physics, 1980-08
A randomized study of split-course radiotheray of lung cancer: long term results.
Journal for immunotherapy of cancer, 2017-11-21
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
J Immunother Cancer, 2021 Feb
Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade.
J Natl Compr Canc Netw,
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.
Ann Oncol,
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
J Immunother Cancer,
Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes.
J Immunother Cancer,
Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis.
J Clin Oncol, 2021 Dec 20
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.
J Natl Compr Canc Netw,
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.
Ann Intern Med,
Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.
Ann Rheum Dis, 2011 Nov 29
Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.
Respir Med, 2012 Apr 09
The treatment of pulmonary sarcoidosis.
Am J Respir Crit Care Med,
Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999.
Arthritis Rheum,
A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
Eur Heart J, 2015 Aug 29
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).
Eur Respir J, 2019 Jan 24
Diagnosis of pulmonary hypertension.
BMJ Open, 2019 May 05
Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts.
Rheumatol Int, 2021 Jan 29
Does methotrexate cause progressive fibrotic interstitial lung disease? A systematic review.
N Engl J Med, 2020 Sep 19
Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer.
J Clin Oncol, 2021 Nov 02
Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With Mutation (IMPACT).
The European respiratory journal, 2014-11
Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis.
Clin Exp Rheumatol, 2019 Nov 20
Use of third-line therapies in advanced sarcoidosis.
N Engl J Med,
Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis.
Lung, 2021 Apr 07
Tofacitinib as a Steroid-Sparing Therapy in Pulmonary Sarcoidosis, an Open-Label Prospective Proof-of-Concept Study.
RMD Open, 2021 Sep
Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey.
JAMA,
Determination of Brain Death/Death by Neurologic Criteria: The World Brain Death Project.
Eur Respir Rev, 2021 Dec 15
Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection.
Ann Am Thorac Soc,
Persistent Post-COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment.
Ann Am Thorac Soc,
Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design.
American journal of respiratory and critical care medicine, 2010-08-01
Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax.
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2002-10
Use of fluticasone in acute symptomatic pulmonary sarcoidosis.
Eur Respir J,
Randomized trial of inhaled fluticasone propionate in chronic stable pulmonary sarcoidosis: a pilot study.
Eur Respir J,
Inhaled budesonide in pulmonary sarcoidosis: a double-blind, placebo-controlled study. Dutch Study Group on Pulmonary Sarcoidosis.
J Intern Med,
No effect of high-dose inhaled steroids in pulmonary sarcoidosis: a double-blind, placebo-controlled study.
Drugs,
Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview.
Eur Respir J, 2021 Dec 16
ERS clinical practice guidelines on treatment of sarcoidosis.
N Engl J Med, 2021 Jan 13
Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease.
Lancet Respir Med, 2021 Jun 29
Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study.
Radiology, 2012-10
Short-term mortality in acute pulmonary embolism: clot burden and signs of right heart dysfunction at CT pulmonary angiography.
The New England journal of medicine, 2014-04-10
Fibrinolysis for patients with intermediate-risk pulmonary embolism.
The American journal of cardiology, 2016-11-15
Relation Among Clot Burden, Right-Sided Heart Strain, and Adverse Events After Acute Pulmonary Embolism.
J Bronchology Interv Pulmonol, 2021 Nov 10
Indwelling Pleural Catheter (IPC) for the Management of Hepatic Hydrothorax: The Known and the Unknown.
Crit Care, 2021 Jul 28
Improving lung compliance by external compression of the chest wall.
N Engl J Med, 2022 Sep 04
Bronchodilators in Tobacco-Exposed Persons with Symptoms and Preserved Lung Function.
Chest, 2015-09
Intrapleural Fibrinolysis for the Treatment of Indwelling Pleural Catheter-Related Symptomatic Loculations: A Multicenter Observational Study.
J Thorac Dis,
The use of thrombolytics in the management of complex pleural fluid collections.
Eur Respir J, 2013 Oct 31
Measuring central pulmonary pressures during exercise in COPD: how to cope with respiratory effects.
Am J Respir Crit Care Med,
Reading pulmonary vascular pressure tracings. How to handle the problems of zero leveling and respiratory swings.
The European respiratory journal, 2015-10
An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features.
Med Mycol, 2010 Jul 22
Severe asthma and fungi: current evidence.
Respirology, 2001 Mar
Allergic bronchopulmonary aspergillosis: new concepts of pathogenesis and treatment.
The European respiratory journal, 2019-01
Risk stratification and medical therapy of pulmonary arterial hypertension.
Eur Respir J, 2019 Jan 24
Pulmonary hypertension in chronic lung disease and hypoxia.
Chest, 2021 Feb
Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren's.
Chest, 2011-06
Rapid pleurodesis for malignant pleural effusions: a pilot study.
JAMA,
Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial.
JAMA,
Effect of Thoracoscopic Talc Poudrage vs Talc Slurry via Chest Tube on Pleurodesis Failure Rate Among Patients With Malignant Pleural Effusions: A Randomized Clinical Trial.
Circulation, 2001-01-02
Balloon pulmonary angioplasty for treatment of chronic thromboembolic pulmonary hypertension.
The European respiratory journal, 2019-05
French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension.
Interv Cardiol Clin,
Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension.
Circ Cardiovasc Qual Outcomes,
Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: Results of a Multicenter Registry.
Eur Respir J, 2017 Jun 08
Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: the initial German experience.
Ann Am Thorac Soc,
Pulmonary Endarterectomy. Patient Selection, Technical Challenges, and Outcomes.
American journal of respiratory and critical care medicine, 2011-02-15
Clinical course and prediction of survival in idiopathic pulmonary fibrosis.
Chest, 2011-07
Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium.
The Lancet. Respiratory medicine, 2017-12
Palliative care in interstitial lung disease: living well.
ERJ Open Res, 2019 Jul 08
Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry.
BMC Pulm Med, 2018 Jan 17
Barriers to timely diagnosis of interstitial lung disease in the real world: the INTENSITY survey.
American journal of respiratory and critical care medicine, 2013-04-01
Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health.
Am J Respir Crit Care Med,
Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.
The European respiratory journal, 2018-08
Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis.
J Am Coll Cardiol,
Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.
N Engl J Med, 2022 Jun 03
Adagrasib in Non-Small-Cell Lung Cancer Harboring a Mutation.
J Clin Oncol, 2022 Jun 03
Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A.
Rheumatology (Oxford, England), 2017-06-01
A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies.
Autoimmun Rev, 2012 Jul 05
Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity.
The Lancet. Respiratory medicine, 2018-08
Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study.
Respir Med, 2011 Sep 13
Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis.
Mayo Clin Proc, 2018 May 24
Short Telomere Syndromes in Clinical Practice: Bridging Bench and Bedside.
Respirology, 2021 Oct 06
Pulmonary fibrosis associated with telomere-related gene mutations: A complex inheritance.
JAMA,
Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output.
Ann Intern Med, 2020 Sep 08
Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia.
Arthritis & rheumatology (Hoboken, N.J.), 2017-03
Progressive Decline of Lung Function in Rheumatoid Arthritis-Associated Interstitial Lung Disease.
Lancet Respir Med, 2021 Jan
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
American journal of respiratory and critical care medicine, 2018-11-01
A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE).
Ann Am Thorac Soc,
The Clinical Significance of Collateral Ventilation.
Chest,
Rationale and design of The National Emphysema Treatment Trial: a prospective randomized trial of lung volume reduction surgery. The National Emphysema Treatment Trial Research Group.
Chest, 1997-01
Pharmacologic hemodynamic support in massive pulmonary embolism.
Pulm Circ, 2021 Jun 14
Levosimendan, milrinone, and dobutamine in experimental acute pulmonary embolism.
Am J Respir Crit Care Med,
Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease.
Annals of the American Thoracic Society, 2015-05
The accuracy of computed tomography to predict completeness of pulmonary fissures. A prospective study.
Int J Chron Obstruct Pulmon Dis, 2020 Jun 09
An Integrative Approach of the Fissure Completeness Score and Chartis Assessment in Endobronchial Valve Treatment for Emphysema.
Am J Respir Crit Care Med,
Determination of cardiac output by the Fick method, thermodilution, and acetylene rebreathing in pulmonary hypertension.
Cochrane Database Syst Rev, 2021 Mar 26
Endothelin receptor antagonists for pulmonary arterial hypertension.
Lupus, 2020 Feb 09
Systemic lupus erythematosus and diffuse alveolar hemorrhage, etiology and novel treatment strategies.
N Engl J Med,
Intrapleural use of tissue plasminogen activator and DNase in pleural infection.
BMC Res Notes, 2020 Aug 03
Clinical efficacy and bleeding outcomes of tissue plasminogen activator and dornase alfa in pleural space infection with once daily concurrent administration: a retrospective cohort study.
Respirology, 2022 Apr 19
Alteplase Dose Assessment for Pleural infection Therapy (ADAPT) Study-2: Use of 2.5 mg alteplase as a starting intrapleural dose.
Lancet Respir Med,
Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society.
Eur Respir Rev, 2022 Apr 13
Incidental discovery of interstitial lung disease: diagnostic approach, surveillance and perspectives.
Future Sci OA, 2020 Aug 03
A retrospective analysis of eosinophilia as a predictive marker of response and toxicity to cancer immunotherapy.
Cancer Treat Res Commun, 2022 Jul 01
Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy.
Trends Immunol, 2021 Mar 10
Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines.
Blood Adv,
American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.
CMAJ,
Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy.
Chest, 2020 Aug 14
Clinical Characteristics of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia: A Retrospective Analysis.
Chest, 2020 Jul
Somatostatin Analogs Improve Respiratory Symptoms in Patients With Diffuse Idiopathic Neuroendocrine Cell Hyperplasia.
ERJ Open Res, 2020 Oct
Constrictive bronchiolitis in diffuse idiopathic pulmonary neuroendocrine cell hyperplasia.
Eur Respir J, 2019 Apr 18
Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials.
Am J Obstet Gynecol MFM, 2021 Mar 27
Pregnancy and pulmonary arterial hypertension: a case series and literature review.
Respirology, 2013 Nov 29
Rituximab in severe, treatment-refractory interstitial lung disease.
Respir Res, 2022 Jun 21
Effect size of rituximab on pulmonary function in the treatment of connective-tissue disease-related interstitial lung disease: a systematic review and meta-analysis.
J Thorac Oncol, 2013 Nov
Radiotherapy for intubated patients with malignant airway obstruction: futile or facilitating extubation?
Practical radiation oncology, 2011
Palliative thoracic radiotherapy in lung cancer: An American Society for Radiation Oncology evidence-based clinical practice guideline.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2017-01
Cancer risk among lung transplant recipients with cystic fibrosis.
N Engl J Med, 2019 Oct 31
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
J Cyst Fibros, 2020 Jul 18
Effect of highly effective modulator treatment on sinonasal symptoms in cystic fibrosis.
Circulation, 2013-07-30
Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study.
The European respiratory journal, 2018-02
Macitentan in pulmonary hypertension due to left ventricular dysfunction.
Circulation, 2011 Jun 27
Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study.
Int J Cardiol, 2019 Jan 04
Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension.
Cochrane Database Syst Rev, 2019 Jan 31
Phosphodiesterase 5 inhibitors for pulmonary hypertension.
Chest, 2014 Nov
Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study.
Circulation, 2021 Feb 08
Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial.
N Engl J Med, 2021 Aug 27
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
ERJ Open Res, 2022 Feb 21
Treatment of pulmonary hypertension associated with COPD: a systematic review.
J Infect Dis, 2020 Jun 11
Interstitial Lung Abnormalities in People With HIV Infection and Uninfected Controls.
Clin Chest Med, 2013 Apr 08
Interstitial lung disease in HIV.
Chest, 2016-03
Technical Aspects of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration: CHEST Guideline and Expert Panel Report.
Chest, 2008 Feb 08
Endobronchial ultrasound-guided transbronchial needle aspiration of lymph nodes in the radiologically and positron emission tomography-normal mediastinum in patients with lung cancer.
JAMA, 2010 Nov 24
Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial.
Eur Respir J, 2017 Sep 09
European Respiratory Society guidelines for the management of adult bronchiectasis.
Thorax, 2019 Jan
British Thoracic Society Guideline for bronchiectasis in adults.
Clin Med Insights Circ Respir Pulm Med, 2021 Mar 30
Delphi Consensus Recommendations on Management of Dosing, Adverse Events, and Comorbidities in the Treatment of Idiopathic Pulmonary Fibrosis with Nintedanib.
Cureus, 2022 Sep 06
Mycophenolate Mofetil-Induced Cytomegalovirus Colitis in a Patient With Polymyositis.
JAMA, 2005-10-05
Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial.
Trials, 2016 Jul 22
Evaluating the efficacy of dexamethasone in the treatment of patients with persistent acute respiratory distress syndrome: study protocol for a randomized controlled trial.
N Engl J Med, 2023 Mar 21
Hydrocortisone in Severe Community-Acquired Pneumonia.
JAMA, 2019-10-01
Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial.

Related Topics

Copyright © 2023 theMednet
All Rights Reserved.